PCDHB16: A Potential Drug Target and Biomarker (G57717)

Target Name: PCDHB16

NCBI ID: G57717

PCDHB16

PCDHB16: A Potential Drug Target and Biomarker

PCDHB16, also known as PCDHbeta 16, is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and expression pattern have made it an attractive target for researchers to investigate, and its functions have been extensively studied in various organisms, including humans.

PCDHB16 is a part of the PCDH gene family, which is known for the formation of a characteristic \"beta-sheet\" structure in its coding regions. PCDH尾16 is unique in that it contains a unique exon, which is not found in any other PCDH尾 genes. This exon is responsible for the formation of a distinct loop-like structure at the end of the gene, which has been named the \"loop 16\" region.

The PCDH尾16 gene has been shown to be involved in various cellular processes, including cell growth, differentiation, and inflammation. It has been shown to play a role in the development and progression of various diseases, including cancer. For example, studies have shown that PCDH尾16 is often expressed in cancer tissues and that it is associated with poor prognosis in cancer patients.

Due to its involvement in various cellular processes and its association with cancer, PCDH尾16 has been considered as a potential drug target. Researchers have been exploring the potential mechanisms of action of drugs that target PCDH尾16 to find new treatments for various diseases. One of the main Strategies being explored is the use of small molecules, such as drugs that can modulate the activity of PCDH尾16, to treat diseases.

Another approach being explored is the use of RNA-based therapies, such as small interfering RNA (siRNA) and CRISPR/Cas9-based therapies, to target PCDH尾16 and silence its expression. These therapies have been shown to be effective in treating various diseases, including cancer. For example, studies have shown that siRNA-based therapies can effectively silence the expression of PCDH尾16 in cancer cells, leading to a reduction in cell proliferation and the inhibition of cancer growth.

In addition to its potential as a drug target, PCDH尾16 has also been identified as a potential biomarker for various diseases. Its unique expression pattern and the fact that it is not found in other PCDH尾 genes make it an attractive candidate for diagnostic tests. Studies have shown that PCDH尾16 is expressed in various tissues and that its expression levels are affected by various factors, including cancer status, tissue type, and treatment.

The expression of PCDH尾16 has also been used as a biomarker for various diseases, including cancer. Studies have shown that PCDH尾16 is often expressed in cancer tissues and that its expression levels are associated with cancer progression and poor prognosis. For example, a study of breast cancer found that PCDH尾16 was expressed in 82% of breast cancer tissues and that its expression levels were associated with the poor prognosis of the disease.

In conclusion, PCDHB16 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases. Its unique structure and expression pattern make it an attractive target for researchers to investigate, and its functions have been extensively studied in various organisms, including humans. Further research is needed to fully understand the potential of PCDH尾16 as a drug target and biomarker for various diseases.

Protein Name: Protocadherin Beta 16

Functions: Potential calcium-dependent cell-adhesion protein. May be involved in the establishment and maintenance of specific neuronal connections in the brain

The "PCDHB16 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PCDHB16 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets